Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This study aims to compare the PK/PD of a single injection of investigational Medicinal
Product (IMP) MSB11456, US licensed Actemra and EU approved RoActemra in healthy adult
subjects.